These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 18932097)
61. Antiangiogenic Targets for Glioblastoma Therapy from a Pre-Clinical Approach, Using Nanoformulations. Nery de Albuquerque Rego G; da Hora Alves A; Penteado Nucci M; Bustamante Mamani J; Anselmo de Oliveira F; Gamarra LF Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32599834 [TBL] [Abstract][Full Text] [Related]
65. Acneiform eruption in a patient receiving bevacizumab for glioblastoma multiforme. Keenan BP; Abuav R Arch Dermatol; 2010 May; 146(5):577. PubMed ID: 20479324 [No Abstract] [Full Text] [Related]
66. Questions regarding the optimal use of bevacizumab in glioblastoma: a moving target. Stupp R; Weller M Neuro Oncol; 2014 Jun; 16(6):765-7. PubMed ID: 24826844 [No Abstract] [Full Text] [Related]
67. Current status of antiangiogenic therapies for glioblastomas. Arrillaga-Romany I; Reardon DA; Wen PY Expert Opin Investig Drugs; 2014 Feb; 23(2):199-210. PubMed ID: 24320142 [TBL] [Abstract][Full Text] [Related]
68. The new cancer blockers. Johns Hopkins Med Lett Health After 50; 2004 Oct; 17(8):1-2, 7. PubMed ID: 15602777 [No Abstract] [Full Text] [Related]
73. A multilayer grow-or-go model for GBM: effects of invasive cells and anti-angiogenesis on growth. Saut O; Lagaert JB; Colin T; Fathallah-Shaykh HM Bull Math Biol; 2014 Sep; 76(9):2306-33. PubMed ID: 25149139 [TBL] [Abstract][Full Text] [Related]
74. Update on bevacizumab and other angiogenesis inhibitors for brain cancer. Rinne ML; Lee EQ; Nayak L; Norden AD; Beroukhim R; Wen PY; Reardon DA Expert Opin Emerg Drugs; 2013 Jun; 18(2):137-53. PubMed ID: 23668489 [TBL] [Abstract][Full Text] [Related]
75. The glioblastoma vasculature as a target for cancer therapy. Dimberg A Biochem Soc Trans; 2014 Dec; 42(6):1647-52. PubMed ID: 25399584 [TBL] [Abstract][Full Text] [Related]
76. Antiangiogenic Therapy for Malignant Brain Tumors: Does It Still Matter? Pellerino A; Bruno F; Soffietti R; Rudà R Curr Oncol Rep; 2023 Jul; 25(7):777-785. PubMed ID: 37071295 [TBL] [Abstract][Full Text] [Related]
77. Treatment of glioblastoma with bevacizumab: has a new standard therapy been defined? Chamberlain MC CNS Drugs; 2011 Oct; 25(10):815-8. PubMed ID: 21936584 [No Abstract] [Full Text] [Related]
78. The evolving role of antiangiogenic therapies in glioblastoma multiforme: current clinical significance and future potential. Anthony C; Mladkova-Suchy N; Adamson DC Expert Opin Investig Drugs; 2019 Sep; 28(9):787-797. PubMed ID: 31356114 [No Abstract] [Full Text] [Related]
79. Is deferred use of bevacizumab for glioblastoma associated with prolonged survival? D'Alessandris QG; Capo G; Pallini R Neuro Oncol; 2014 Oct; 16(10):1427. PubMed ID: 25053854 [No Abstract] [Full Text] [Related]
80. Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. Piccioni DE; Lai A Neuro Oncol; 2014 Oct; 16(10):1427-8. PubMed ID: 25155359 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]